Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 ...Continue Reading
Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection
The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains
The viral spike protein is not involved in the polarized sorting of coronaviruses in epithelial cells
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants
Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge
Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins
Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions
Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy.
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice
Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development.
Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.
Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics.
High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay.
Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naïve semisynthetic library.
Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds.
Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation.
COVIDep: a web-based platform for real-time reporting of vaccine target recommendations for SARS-CoV-2
Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.
Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation.
Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding.
Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses
Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity
Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.
Antibody-Dependent Cell Cytotoxicity
Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.
Cancer Biology: Molecular Imaging
Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.